Partial Response to PPI treatment: The Cost to Society and the Burden to the Patient - a study in France - REMAIN

Study identifier:D9120N00013

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Partial Response to PPI treatment: The Cost to Society and the Burden to the Patient

Medical condition

Gastroesophageal Reflux Disease

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

275

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Feb 2009
Primary Completion Date: 01 Nov 2010
Study Completion Date: 01 Nov 2010

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

i3 Innovus

Inclusion and exclusion criteria